Last reviewed · How we verify
ILX651
ILX651 is a small molecule inhibitor of the sodium-iodide symporter (NIS) with potential use in thyroid cancer treatment.
ILX651 is a small molecule inhibitor of the sodium-iodide symporter (NIS) with potential use in thyroid cancer treatment. Used for Thyroid cancer.
At a glance
| Generic name | ILX651 |
|---|---|
| Sponsor | Genzyme, a Sanofi Company |
| Drug class | NIS inhibitor |
| Target | NIS |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
ILX651 works by inhibiting the sodium-iodide symporter (NIS), a protein responsible for the uptake of iodine in thyroid cells. This inhibition can lead to a reduction in iodine uptake and potentially reduce the growth of thyroid cancer cells.
Approved indications
- Thyroid cancer
Common side effects
- Unknown
Key clinical trials
- Study of ILX651 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma (PHASE2)
- Study of ILX651 in Patients With Hormone-Refractory Prostate Cancer Previously Treated With Docetaxel (PHASE2)
- Study of ILX651 in Patients With Inoperable Locally Advanced or Metastatic Melanoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ILX651 CI brief — competitive landscape report
- ILX651 updates RSS · CI watch RSS
- Genzyme, a Sanofi Company portfolio CI